RU2001616C1 - Agent for treatment cardiovascular insufficiency - Google Patents

Abstract

Usage: the invention relates to medicine, namely to the pharmaceutical industry and relates to an agent for the treatment of cardiovascular failure. The purpose of the invention is to increase specific activity. The essence of the invention consists in the preparation of an agent consisting of tauron and filler - potato starch, gelatin, microcrystalline cellulose, aerosil and calcium stearic acid. taken at certain ratios The beneficial effect is to expand the field of application in the treatment of cardiovascular failure

Description

The invention relates to the field of medicine, particularly to preparations for treating cardiovascular failure (CCH).

Among the non-steroidal anabolic preparations currently used for the treatment of CCH, one can mention riboxin and potassium orotate, which are accepted as the prototype.

Potassium orotate tablets consist of the active principle of potassium orotate (potassium salt of uracil-4-carboxylic acid), excipients, milk sugar, potato starch, gelatin, stearic acid in the following proportions in g per 1 tablet:

Potassium Orotat 0.5 g

Milk sugar0.066 g

Potato starch 0.172 g Gelatin and acid Before preparation

stearin tablets

weighing 0.75 g

However, the effect of these preparations does not always achieve the expected effect and, moreover, does not completely satisfy from the point of view of contraindications and the side effect factor.

An object of the present invention is to increase specific activity.

This goal is achieved by obtaining tablets based on the active principle of taufon (2-aminoethanesulfonic acid), which additionally includes microcrystalline cellulose, potato starch, aerosil, calcium stearic acid and gelatin in the following mass ratios, g per 1 tablet:

0.238 0.263

Taufon Cellulose microcrystalline Potato starch Aerosil Calcium stearate Gelatin Tablet weight

This composition provides tablet strength, disintegration within 1-2 minutes, rapid and complete release of the active principle, which contributes to the greater effectiveness of the drug.

The conversion of the mass ratios in g per tablet, wt.% Was carried out according to the formula

0.024

0.013 0.001

0.002 0.005

0.283

0,026

0.015 0.003

0.004 0.007

0.318

hell

mi

mi + gl2 +

100.

0

Taufon Cellulose microcrystalline Potato starch Aerosil

Calcium Stearate Gelatin Total

. + mi

gm.%

0.238-0.263 84.09-82.7

0.024-0.026 8.48-8.2

0.013-0.015 4.59-4.72 0.001-0.003 0.353-0.95 0.002-0.004 0.71-1.3 0.005-0.007 1.77-2.2 0.283-0.318 99.99-100.0

5

0

5

0

5

0

5

0

5

Taufon drug trials in the treatment of congestive heart failure.

To simulate congestive heart failure, we used male chinchilla rabbits weighing about 3 kg, which damaged the aortic valve through a special perforator through the right carotid artery. The animals were taken in the experiment, in which the pulse pressure after valvotomy increased by 75%. One month after the operation, 5 groups were formed from rabbits with signs of left ventricular overload, which was recorded on an electrocardiogram.

The first group consisted of 18 animals that were not subsequently treated.

The second group, 18 rabbits, received taufon at a dose of 100 mg / kg daily for 2 months.

A third group of -18 rabbits received taufon at a dose of 10 mg / kg for 2 months.

The fourth group - 18 rabbits received potassium orotate (100 mg / kg) daily instead of taufon.

The fifth group, the control one, was composed of 15 falsely operated animals with intact valves, which were kept on the same food ration for 2 months, but without drug additives.

Three months after the operation, all remaining rabbits were used for acute experiments to evaluate the pumping function of the left ventricle, the maximum blood flow velocity in the aorta at zero pressure, to determine the inotropic state and the degree of change in myocardial reactivity.

The data obtained were subjected to statistical analysis using Student's criteria.

The overall mortality in group 1 animals left untreated was 50% by 12 weeks after valve damage. Of the 18 rabbits, 9 died. About the same

mortality (45%) in the potassium orotate group: 10 out of 18 rabbits survived.

Among animals treated with taufon, mortality was significantly lower. At a dose of 10 mg / kg, 2 rabbits out of 18 died, and at a dose of 100 mg / kg, all 18 animals remained alive.

The autopsy of dead animals showed the presence of severe ascites, hydrothorax, pericarditis, in many cases cirrhosis of the liver and pulmonary edema were also observed.

The average values of body weight, heart weight, and also showed hemodynamics, measured 12 weeks after surgery, are presented in table 1.

The total weight of untreated rabbits was on average 20% higher compared with the weight of animals treated with large doses of taufon. This happened, probably due to the fact that in animals treated with taufon, the fluid content in the body was significantly reduced. Thus, while in the chest and abdominal cavities of rabbits without treatment, as a rule, 100-200 ml of serous fluid was contained, and the tissues were postious, this was not observed in rabbits receiving taufon.

The weight of the heart in all groups with damaged valves, with the exception of animals treated with taufon, was about 1.5 times higher than in the control group of false-operated rabbits (P 0.01). In animals without treatment, the average heart weight was 16.2 ± 1.3 g. When treated with taufone at a dose of 10 mg / kg, the heart weight decreased to 14.4 ± 1.4 g, and at a dose of 100 mg / kg to 11.9 ± 1.1 g, i.e. it decreased sufficiently (P 0.01) compared to the weight of the heart in animals without treatment.

When treated with potassium orotate, the total weight of the animals and the weight of the heart did not differ much from animals without treatment.

The frequency of contractions three months after surgery in awake animals in all groups with aortic regurgitation was increased compared with the control group. But if in animals in the untreated group, as well as in rabbits receiving a lower dose of taufon and potassium orotate, the reduction rate was increased by an average of 14%, then when treated with a higher dose of taufon, only 3%.

Systemic blood pressure, as well as systolic pressure in the left ventricle in all animals with aortic valvutomy was slightly lower than normal values (on average by 10-12%). The reverse dynamics is observed in changes in diastolic pressure in the left ventricle. In all animals with a pathology, it was increased: without treatment and when treated with a comparison drug - by 3–3.5 times, for treatment with taufon less than 2 times.

The minute volume index (MO / body weight) in all animals with aortic regurgitation was reduced. But if in animals without

0 treatment and when treated with potassium orotate, it was reduced by 42-43% (P 0.01), then with taufon treatment it was only 16-20% (P 0.5).

A similar picture is revealed for

5 consideration of parameters characterizing contractility of the left ventricle. The values of the maximum rate of contraction and relaxation were reduced by an average of 30-40% in animals with damaged

0 valves. Taufon at a dose of 100 mg / kg almost normalized these parameters of the contractile activity of the heart. The rate of contraction in animals treated with taufon increased by 37% compared with untreated animals. The rate of relaxation of the left ventricle increased even more (by an average of 63%). When treated with potassium orotate, as well as with a small dose of taufon, the changes in the velocity parameters of pressure were significantly less. The contraction rate increased by only 13% compared to untreated animals, and the relaxation rate increased by 26%. Contractility Index (max dp / dt / P) and

5, the relaxation index (mln dp / dt / P) in rabbits with deficiency decreases on average by 24 and 21%, respectively. When treated with taufon, these parameters were completely restored, at the same time with the introduction of

0 potassium orotate showed only a tendency to increase indices.

The state of the pumping function of the left ventricle, estimated using postload characteristics, also significantly improved in the treatment of animals with taufon. Under pathological conditions, all postload curves are shifted up and to the left. With heart failure without treatment and with the administration of potassium orotate, the rate of increase (maximum blood flow velocity in the aorta at zero outlet pressure) increased by an average of 24%. and power (maximum isometric voltage at zero blood flow)

5 decreased on average by 17%. In animals treated with 100 mg / kg taufon, the speed indicator significantly decreased, and the power indicator increased, approaching normal values. As a result, the load curve was shifted down toward the normal curve. Thus, taufon, normalizing the function of the heart, restored the potential, i.e. the ability of the heart to develop greater pressure.

The administration of potassium orotate had practically no effect on the position of the postload curve. It was the same as in animals with pathology without treatment.

A study of the functional state of the heart in acute experiments showed that animals taking taufon showed normalization of heart responses to frequency stimulation, volume loading, and intravenous administration of calcium ions and catecholamines.

The change in hemodynamic parameters in moderate tachycardia in animals with congestive heart failure without treatment (CHF) and in those receiving taufon (CHF + taufon), potassium orotate (CHF + orotate K) and in animals without pathology (control) are given in Table. 2.

So, with a moderate (average 15%) increase in heart rate by electrostimulation in animals with congestive heart failure (CHF), there is a decrease in blood pressure and pressure in the left ventricle by 20-25 mm Hg, and the minute volume index is more than than 2 times (p 0.02). At the same time, the rate of contraction, relaxation, and the left ventricular contractility index are reduced by an average of 20-25% (p 0.05). The values of diastolic pressure in the left ventricle are not considered, because their changes at such high rhythms are difficult to evaluate with a high degree of accuracy.

A deterioration in hemodynamics and contractility in response to an increase in heart rate was also observed in groups of animals treated with teufon at a dose of 10 mg / kg and potassium orotate comparison drug. It should be noted that in the latter quite often during the experiments spontaneous rhythm disturbances occurred, and in 2 cases out of 7 even fibrillation occurred. There is practically no spontaneous occurrence of fibrillation in rabbits; therefore, the observed seizures can be explained only by the fact that these animals were treated with potassium orotate.

Animals treated with taufon at a dose of 100 mg / kg did not have rhythm disturbances, absorbed the increased heart rate during electrostimulation quite well, and their hemodynamic parameters were closer to the control group. Blood pressure and pressure in the left ventricle, indices of minute volume index (max dp / dt, mln dp / dt), and contractility index with moderate tachycardia in this group almost did not change on average, and in some cases even increased. The latter fact can be considered as the restoration of the chronoinotropic dependence characteristic of normal hearts.

With a volumetric load of the heart achieved by intravenous administration of 5 ml of physiological saline, in animals treated with taufon (100 mg / kg), the heart response was close to normal. A slight increase in systolic pressure by 10-15 mmHg), as a rule, was not accompanied by an increase in diastolic pressure. The same volume load in animals without treatment and in those receiving potassium orotate caused a significant increase in diastolic pressure (from 9.0 ± 0.5 to 14.5 ± 0.7), while the pulse pressure and cardiac output did not rise.

The restoration of normal cardiac reactivity after a course of treatment with taufon om was also traced from the results of experiments in which calcium chloride was intravenously administered to animals (Table 3). As is known, the normal addition of Ca ions increases myocardial contractility: the systolic dependence of contraction and relaxation increases, and the contractility index increases. However, in animals with CHF, the administration of Ca ions did not improve left ventricular contractility parameters, and even a tendency to worsen this process with respect to the rate of relaxation. In some experiments, the rate of relaxation slowed down by 20-30%, relaxation became incomplete, and each subsequent reduction began against the background of the unfinished previous. The observed picture resembles the effect of an overdose of calcium.

Calcium chloride reacted almost equally to the intravenous administration of rabbits receiving the reference drug.

At the same time, the reaction of animals receiving taufon. was closer to the reaction of normal animals. All indicators of contractility, if not to the extent that the control animals, significantly increased.

The restoration of the normal reaction to Ca2 + is due to the fact that taufon therapy in heart failure prevents excessive saturation of myocardial cells with calcium.

There is convincing evidence in the literature of the protective effect of taufon upon perfusion of the heart with an environment with a sharply changed content of calcium ions,

The results of experiments in which adrenaline (Table 4) was administered to animals was given to tayuka to verify the cardiac reactivity after treatment with taufon. If in animals with CHF without treatment with taufon and in those receiving potassium orotate, the pressure in the left ventricle, the rate of contraction and relaxation, and the contractility index increased by no more than 15-20% in response to the introduction of a standard dose of adrenaline, then after treatment taufon reactivity of the heart increased almost 2 times. All the studied parameters from the administration of the same dose of adrenaline increased by 40-50%, to the same extent as in the control group.

An analysis of the data shows that treatment of animals with artificial aortic valve insufficiency with taufon increases their life expectancy; improves overall hemodynamics; restores pumping function and myocardial contractility; helps maintain relatively normal regulation of contractile activity and heart reactivity.

Determination of the acute toxicity of taufon in mice when administered by mouth showed that its LD50 was more than 10 g / kg.

The study of chronic toxicity of taufon was carried out by oral administration on nonlinear white rats of the general sex, weighing 150-200 g for 6 months. Pathomorphological studies of slaughtered animals did not reveal a side effect of the drug.

A study of the embryotoxic effect of taufon upon administration of animals at different doses and at different stages of pregnancy (before implantation, plantation initiation, organogenesis, phenogenesis) on outbred white rats - females weighing 160-180 g showed that the drug is harmless with prolonged use.

In mice of the EDC line — weighing 25 g at a dose of 1 g per 1 kg of animal weight, the effect of the drug on the chromosomal bone marrow cells was studied. At the same time, no increase in the number of chromosomal lesions was revealed compared with the control group.

The results of the treatment of patients with cardiovascular diseases complicated by the development of chronic circulatory failure (Kharkov Institute of Therapy).

The overall clinical efficacy of the drug was evaluated individually for each patient on the following scale.

An excellent effect is a significant improvement in the general clinical condition of the patient, easing shortness of breath, palpitations, a significant increase in exercise tolerance by 75-100%, stabilization of blood pressure at normal or near normal numbers.

A good effect is clinical improvement, an increase in exercise tolerance by 25%, stabilization of blood pressure at close to normal numbers.

A satisfactory effect is a certain subjective improvement without a clear increase in exercise tolerance, a slight decrease in blood pressure.

Lack of effect.

The study did not include patients with diseases of the gastrointestinal tract and other pathologies that could interfere with the absorption process and the metabolism of the drug. The taufon preparation was administered at a dose of 0.25 g twice daily 20 minutes before meals. The average duration of treatment was 28.3 ± 2.7 days, of which 14.6 ± 1.6 days in hospital and 13.7 ± 1.1 days on an outpatient basis. Only men were included in the survey, as recommended by the lead organization. In the case of irregular administration of the drug, as well as its intolerance, patients were excluded from the study.

45 patients were monitored, among whom 25 people received taufon therapy and 20 patients (control group) received potassium orotate (reference drug), 0.5 g twice daily. Both drugs were treated against the background of traditional antianginal therapy, including peripheral vasodilators, calcium antagonists, if necessary beta-blockers, as well as the use of diuretics and cardiac glycosides.

The main group of patients was 25 people, the average age of which was 58.3 ± 2.2 years, among which signs of circulatory failure of stage II A were detected in 15 patients and circulatory failure of stage II B in 10 patients. Idiopathic dilated cardiomyopathy was determined in 4 patients (16%). In 5 patients, progressive angina pectoris and rest were determined (20%); in 16 patients, stable angina pectoris was detected (64%). The distribution of functional classes (according to the classification of the Canadian Association of Cardiology) is presented as follows: II functional class - 1 patient (4%); Functional class III - 11 patients (44%); IV functional class -4 patients (16%).

10 patients had a history of large-focal myocardial infarction (40%). Hypertension was detected in 15 patients (60%). Rhythm disturbance in the form of ventricular extrasystolic arrhythmia was observed in 9 patients (36%).

The control group consisted of 20 patients, the average age of which was 57.6 ± 2.1 years. Of these, in 10 people signs of circulatory failure of stage II A were detected and in 10 patients - signs of circulatory failure of stage II B. In 8 patients, a progressive angina of tension and rest was detected, which amounted to (40%). The distribution of functional classes is as follows: II functional class - t patient (5%); HI functional class - 10 patients (50%). IV functional class - 1 patient (5%).

11 patients of the control group suffered a large focal myocardial infarction, which is 55%. 5 patients (25%) had aneurysm of the heart. Rhythm disturbances in the form of ventricular extrasystolic arrhythmia were detected in 5 people (25%). Hypertension was noted in 15 people (75%).

In the patients included in the study, both the symptoms of coronary atherosclerosis and the dysfunction of the cardiovascular system were quite clearly defined, which justified the search for new, pathogenetically substantiated treatment methods.

Studies have shown that the drug can be used against the background of traditional antianginal therapy, including calcium nitrates and antagonists - 8 patients (32%), nitrates, calcium antagonists and beta-blockers - 3 patients (12%). as well as in combination with calcium nitrate antagonists and diuretics, 6 patients (24%) nitrates, calcium antagonists, diuretic and cardiac glycosides - 8 patients (32%)

Cali orotate was used against the background of the following therapy: nitrates and calcium antagonists - 1 patient (5%). nitrates, calcium antagonists and beta-blockers - 3 patients (5%). nitrates, calcium antagonists and diuretics - 16 patients (65%). calcium antagonists, diuretic and cardiac glycoeids - 3 patients (15%)

During treatment with taufon, there was a decrease in attacks of paroxysmal dyspnea at night (from 3.3 ± 0.51 to 1.1 ± 0.50). dyspnea attacks alone (with

3.29 ± 2.1 to 2.33 ± 2.0), a decrease in the severity of dyspnea during physical exertion, an increase in working capacity, which contributed to improving the quality of life of patients.

0 In the control group, the number of dyspnea attacks at night also decreased from 4.1 ± 1.1 to 2.9 ± 1.1 and the number of dyspnea attacks at rest from 7.9 ± 1.09 to 6.54 ± 1.30.

5 In the main group of patients with the appointment of taufon in 5 patients (20%), a decrease in the signs of digital intoxication was noted: the disappearance of nausea, a decrease in ventricular zxstrasystole in 1 minute.

0 in one patient during treatment with taufon, it became possible to reduce the dosage of digoxin from 0.5 mg to 0.25 mg.

In 10 patients (40%) of the main group, ventricular extrasystoles were detected

5 (9.1 ± 1.69 in 1 min, p 0.05). After treatment, their number decreased to 2.57 ± 1.68 in 1 min, p 0.05.

Patients of the main and control groups were measured blood pressure and studied

moose systolic blood pressure

(SBP) and diastolic pressure (DBP), as well as heart rate before treatment, on days 13-16 and after 25-31 days of course treatment. This data

5 are presented in table. 5

As follows from the table of reliable differences in the parameters of GARDEN. DBP, heart rate during treatment between the main and control groups of patients was not detected.

0 As a result of treatment of patients of the main group, there was a slight increase in potassium ions of blood plasma from 3.89 ± 0.42 to 4.28 ± 0.42 mmol / L. p 0.05. In the control group, plasma potassium was 5 p l 4.1 ± 0.63 mmol / l and after course treatment 4 19 ± 0.62 mmol / l. p 0.05. Significant differences in changes in blood plasma sodium, as well as indicators of lipid metabolism, in particular, total cholesterol. in the main and control groups not detected

During treatment of patients of the main group, the blood glucose level slightly decreased from 5.1 ± 0.43 to 4.6 ± 0.44 mmol / l, p

5 0.05. and in the control group from 4.68 ± 0.34 to 4 4 ± 0 33 mmol / l.

In order to study the peculiarities of the action of the taufon preparation, 9 patients underwent a test with dosed physical activity on a bicycle ergometer before treatment, after 13-16 day and 25-31 day course use of it. At the same time, bicycle ergometry was performed for 7 patients of the control group.

When treating patients of the main and control groups, both after a 13-16 day course and after a 25-31 day course, the total time of work significantly increased, the work performed (from 1125 ± 14.29 to 1800 ± 14.5 kg / m in the main group, p 0.05), initial DP (from 92.3 ± 0.71 to 157.6 ± 2.05 in the main group), threshold threshold (from 91 ± 0.72 to 167.3 ± 2.04 in the main group ), which characterizes an increase in the coronary reserve of the myocardium, the time of the onset of ST segment depression, a decrease in the intensity and duration of the pain attack was noted. Positive dynamics was somewhat more pronounced in the main group than in the control group, however, no statistically significant difference was found here.

The dynamics of changes in central hemodynamics and intracardiac kinetics in the main and control groups was as follows. In the main group, after 13-16 days of treatment and course treatment, there were no significant changes in such indicators as% AS, Vcf. although there was a tendency for them to increase slightly, the left ventricular CRD in both cases was practically unchanged, while the CRC after the course of treatment significantly decreased, and the PV increased significantly (p 0.05). This indicates a slight improvement in myocardial contractile function under the influence of therapy in combination with taufon. In the group of patients who received potassium orotate, there was a statistically significant difference after 13-16 days and course treatment of patients with PV, CDD. % AS, Vcf not detected.

During tetrapolar thoracic rheography in patients receiving taufon. there was a significant increase in stroke volume after the course of treatment (from 48.10 ± 2.37 to 59.9 ± 2.36 ml), minute volume (from 3.38 ± 0.59 to 4.21 ± 0.6 L x hmin) , as well as a decrease in the SPS from 36.72 ± 22.38 to 25.08 ± 22.36 min s. These data suggest that, while taking taufon, the pumping function of the heart is slightly increased. In the control group, the stroke volume and minute volume increased slightly, and the decrease in SPS was even smaller in comparison with the main group.

Researchers at the Kharkov Institute of Therapy believe that clinical efficacy was as follows. Excellent and good results were obtained in general in 78% of patients, while an excellent effect in a larger percentage of cases (54.5% versus 16.6%) was observed in patients with chronic 5 coronary heart disease, complicated by the development of chronic circulatory failure stage II A. In a subgroup of patients with chronic circulatory failure II stage II in 7.4% of cases

0 marked inefficiency of the drug taufon in combination with other drugs.

At the end of the taufon treatment, a withdrawal phenomenon was not observed. Besides

Moreover, during treatment with taufon no side effects of the drug were revealed.

A number of effects of the drug have been noted that can play a positive role in the treatment of patients. So, almost everything

0 patients noted an improvement in appetite, mood, increased performance.

At the clinic of the Kharkov Research Institute of Therapy, clinical trials of a new

5 metabolic drug taufon.

For this purpose, 45 patients with chronic coronary heart disease and idiopathic dilated cardiomyopathy complicated by development were examined.

0 circulatory failure, of which 25 patients received complex therapy (long-acting nitrates, calcium antagonists, cardiac glycosides, diuretics, as well as beta-blockers if necessary), including taufon and 20 patients of the control group who received comparison drug potassium compared to main therapy orotat. In 21 patients of the main group, chronic ischemic heart disease was detected, in 4 patients - idiopathic dilated cardiomyopathy. In 10 patients of the main group, hypertensive disease of the II and III stages was observed according to the WHO classification.

5 Taufon was administered 0.5 g per day for 25-31 days. Potassium orotate was administered 0.5 g 2 times a day, i.e. 1.0 g per day. In the presence of a positive effect of the drug, the period of its use increased

0 to 56 days (2 patients, 8%).

The effect of the drug taufon was evaluated as excellent in 16% of cases, good in 56% of cases, satisfactory in 24% of cases. In 1 patient (4%) with diffuse aneurysm5, my left ventricle was ineffective. In general, in the main group. excellent and good results were achieved in 72% of patients, expressed in the disappearance and reduction of shortness of breath, peripheral edema, congestive edema, congestive phenomena in the young circle of blood circulation against the background of previous therapy with cardiac glycosides and diuretics

20% of patients of the main group showed a decrease in signs of digitalis intoxication, 40% antiarrhythmic effect (decrease in the treatment of ventricular extrasystoles in 1 min)

Studies have shown that taufon is an effective drug. contributing to the improvement of the contractile and pumping function of the myocardium improving the indicators of general hemodynamics

Side effects in the treatment of taufon have not been identified.

Thus, taufon (teukard), a new metabolic preparation based on natural taurine, is an effective drug for the treatment of patients with circulatory insufficiency II A and II B stndii. In 72% of cases, we obtained a positive effect, expressed in the disappearance and reduction of peripheral dyspnea edema, congestion in the pulmonary circulation In some patients (4 people) suffering from idiopathic dilated cardiomyopathy while treating with taufon, an improvement in the general condition was noted ezhenie cardiac function, reducing t zhes thrust arrhythmic disorders (reduction in the number of extrasystoles in 1 min)

The use of taufon is possible in combination with long-acting nitrates of calcium cardiac glycosides and diuretics. Taufonz in combination with other drugs increases the motor activity of patients, reduces the severity of dyspnea at rest and during exercise, and stabilizes a number of hemodynamic and metabolic lohaztel. The drug taufon can be prescribed patients with chronic ischemic disease of the II and II stages

The absence of side effects of the v-withdrawal phenomenon allows taufon to be widely used in the complex treatment of chronic coronary heart disease complicated by the development of chronic circulatory failure stage II and II b as well as idiopathic dilated cardiomyopathy in both inpatient and outpatient settings

 Other data were obtained at the Cardiology Scientific Center of RAMS

Based on the separation of circulatory failure and myocardial disease

Institute of Clinical Cardiology AL M snikova KSC RAMS conducted clinical trials of a new metabolic drug taukard tablets of 025 g

Twenty patients with dilated cardiomyopathy and circulatory failure stage I-III were examined. All patients. included in the study received complex therapy (cardiac glycosides.

diuretics vasodilators). The drug taucard was prescribed in a daily dose of 1 g (0 25 g x 4 times a day) for 30 days. Eight patients underwent repeated taucard therapy in the same

dosage and duration

The taucard effect was evaluated as satisfactory in 20% of cases. The effect was expressed in reducing shortness of breath, peripheral edema of congestive events in the pulmonary circulation and improving the subjective condition of the patient.

Studies have shown. that taucard in combination with complex therapy improves the condition

patients according to objective criteria (contractile and pumping ability of the myocardium) and according to the subjective sensations of patients

Side effects with the use of thaukard not detected

Conclusions of the study at the cardiological scientific center of RAMS

Teukard improves myocardial contractile and pump function

l in combination with complex therapy In almost all patients with stage I-II NK, the drug improves the subjective state of patients (increases tolerance to physical stress, reduces shortness of breath

pain in the region of the heart) The use of taucard against the background of complex therapy of circulatory failure contributes to the potentiation of the action of diuretics, the aucard does not have antiarrhythmic properties; . YART POTENTIAL

(56) M Shkovsky MD D Medicinal tools M, Medicine 1984 t 2 s 140

Table 1

table 2

Continuation of the table. 2

Table 3

Table 4

 The results of indicators before and after treatment are reliable 05

Claims (1)

The claims Means for the treatment of cardiovascular insufficiency, including an active principle and an excipient - potato starch and gelatin, characterized in that, in order to increase specific activity, taufon is used as an active principle, and microcrystalline is used as an excipient. Table 5 cellulose, aerosil and calcium stearic acid in the following ratio of components, wt.%: Taufon82.7 - 84.09 Potato starch 4.59 - 4.72 Gelatin 1.77-2.2 Microcrystalline cellulose8, 2-8.48 Aerosil 0.353-0.95 Calcium stearic acid 0.71 -1.3